MBABANE – New global guidelines on HIV prevention using long-acting injectable medication have been unveiled by the World Health Organisation during an international HIV science conference in Kigali, Rwanda.
The National Emergency Response Council on HIV and AIDS (NERCHA) reported that the guidelines focus on the use of Lenacapavir, a long-acting injectable pre-exposure prophylaxis (PrEP), as well as updated testing strategies to strengthen HIV prevention efforts.
NERCHA National Executive Director Dr. Nondumiso Ncube and Director of HIV Response and Coordination Dr. Bongani Zakhele Masango are attending the 13th International AIDS Society (IAS) Conference on HIV Science, which is currently underway in Rwanda.
The IAS conference, known as the leading global platform on HIV research, is hosted every two years and brings together scientists, health officials, and policymakers to explore the latest developments in HIV treatment and prevention. This year’s meeting features research focused on converting scientific breakthroughs into practical health solutions.
Discussion about this post